Three Way Takeover Battle: Teva plans raising Mylan bid to $43 billion – report

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), the Israeli drugmaker, is preparing to improved proposal for US rival Mylan to as much as $43 billion, $86 to $88 a share, as soon as this More...

Three Way Takeover Battle: Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced on Friday that it has completed the purchase of a 4.61% More...

Three Way Takeover Battle: Teva’s Mylan stake up to 4.3%

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) continues to accumulate shares in takeover target Mylan (MYL), even as Mylan’s largest shareholder, Abbott Labs (NYSE: ABT), announced More...